Enjoy complimentary customisation on priority with our Enterprise License!
Some of the key findings from our hemoglobinopathies treatment market forecast report are summarized below
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
The unavailability of an effective treatment without any or few side effects is encouraging pharmaceutical companies to develop promising therapeutics for hemoglobinopathies treatment. For instance, trial and subject recruiting are ongoing for Phase III of a randomized, parallel group, double-blind, multicenter study by AstraZeneca. This study is expected to be completed by November 2020 and is aimed at evaluating the efficacy of ticagrelor versus placebo in reducing vaso-occlusive crises rate in SCD pediatric patients. The development of luspatercept (ACE-536) by CELGENE for the treatment of transfusion-dependent β-thalassemia is also in Phase III stage. Similarly, several other late-stage pipeline molecules are expected to be available during the next five years.
The current lack of approved therapies will further boost the demand for hemoglobinopathies treatment market growth. The global hemoglobinopathies treatment is expected to grow at a CAGR of almost 11% during the forecast period.
The global hemoglobinopathies treatment market is moderately concentrated and the market being in a growth phase, the competition among companies is intense. To help clients improve their revenue shares in the market, this research report provides an analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this hemoglobinopathies treatment market analysis report suggests strategies companies can follow and recommends key areas they should focus on, to make the most of upcoming growth opportunities.
The report offers a detailed analysis of several leading companies, including:
The sickle cell disease (SCD) segment will account for the highest share in the hemoglobinopathies treatment market because of the recent drug approvals for the treatment of SCD. Additionally, the report also provides an accurate prediction of the contribution of the various types of segments to the growth of the hemoglobinopathies treatment market size.
A complete study of the growth opportunities in the hemoglobinopathies treatment market indicates, the Americas will account for the highest growth of the hemoglobinopathies treatment market throughout the forecast period. Increasing awareness of thalassemia and the growing prevalence of SCD are some of the factors driving hemoglobinopathies treatment market growth in this region.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DRIVERS AND CHALLENGES
PART 10: VENDOR LANDSCAPE
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.